Skip to content
In April 2025, the Department of Health and Human Services (HHS) announced it would disband the Advisory Committee on Heritable Disorders in Newborns and […]
Patient’s mother advocates for newborn screening program reform Read More »
Legislation introduced by Senators John Barrasso (R-WY) and Martin Heinrich (D-NM) would help protect the research and development of new treatments for patients with
Senators introduce bipartisan bill to protect new medicines for rare disease Read More »
A group led by the Biotechnology Innovation Organization (BIO) will recommend new international guidelines for manufacturers of cell and gene therapies (CGT) to support
BIO group to suggest global guidelines for regulating cell and gene therapies Read More »
May is Arthritis Awareness Month, and in observance, Bio.News asked AiArthritis to discuss how it is advancing the needs of patients with autoimmune and
Arthritis Awareness Month: AiArthritis puts a focus on patients Read More »
Starting and running a patient advocacy organization is a massive undertaking. It often includes fundraising, standing up and operating a board and non-profit structure,
BIO Coffee Chat offers advice on launching a successful patient advocacy organization Read More »
Lawmakers questioned Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on key issues like vaccines, biosecurity, and federal research funds in a
Lawmakers question Kennedy on vaccines, biosecurity, and NIH cuts Read More »
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s “MAHA Report: Make Our Children Healthy Again,” released May 22, identifies the Trump administration’s
MAHA report takes issue with industry-funded research Read More »
Legislation to encourage rare disease drug development, enable tax deductions for research, and put checks on middlemen who drive up drug prices moved forward
House advances legislation on PBM reform, orphan drug support, R&D deductions Read More »
Tariffs on pharmaceuticals would harm supply chains that ensure we have enough medicines while threatening America’s security, economy, and biotech leadership, the Biotechnology Innovation
BIO’s comments on tariffs: There are better ways to strengthen U.S. biotech Read More »
Speaking on a recent Endpoints News panel, Nkarta CEO Paul Hastings discussed the impact of regulatory uncertainty and federal funding cuts on the investment
Nkarta’s Hastings discusses environment for biotech funding in Endpoints panel Read More »
